Physician profile
Stephen T Walker
NPI 1265402572
$16,719.16
in general payments reported to CMS, 2019-2025
57 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,069 · 2020: $2,267 · 2021: $3,098 · 2022: $2,440 · 2023: $2,433 · 2024: $2,525 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,844.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,715.26 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,821.93 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,184.03 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $1,152.88 | 2019-2025 | |
| Lilly USA, LLC | $1,093.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $795.98 | 2019-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Abbvie INC. | $746.80 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $698.29 | 2019-2023 | Jardiance, Glyxambi, Synjardy |
| Otsuka America Pharmaceutical, INC. | $588.73 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $476.17 | 2019-2023 | |
| Astellas Pharma US INC | $460.19 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $381.17 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Mylan Specialty L.P. | $339.74 | 2020-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $331.87 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $288.85 | 2019-2025 | Trintellix |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.